NON-SMALL CELL LUNG CANCER (NSCLC)

This phase 2 trial tests whether a low dose of radiation (12 Gy in 3 fractions) combined with one dose of the immunotherapy drug durvalumab can boost the immune system's attack on lung cancer cells before surgery. The study enrolls people with stage 2 or 3 non-small cell lung can…

This study tested whether adding tiragolumab to atezolizumab could help prevent lung cancer from returning after surgery and chemotherapy. It included 56 adults with a specific type of lung cancer (PD-L1 positive, stages IIB to IIIB). The trial was terminated early, so results ar…

This study tested an experimental drug called cofetuzumab pelidotin for people with a specific type of advanced lung cancer (non-small cell lung cancer) that had returned after other treatments. The drug was designed to target a protein called PTK7 found on cancer cells. The stud…

This study tested a wearable device that sends low-intensity electric fields to tumors, combined with the immunotherapy drug pembrolizumab, in people with advanced non-small cell lung cancer that had already been treated with chemotherapy and immunotherapy. The goal was to see if…

This early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cet…

This phase 2 trial tested two immunotherapy drugs (tiragolumab and atezolizumab) with or without chemotherapy in 50 people with early-stage non-small cell lung cancer that could be surgically removed. The goal was to see if the treatment shrank tumors before surgery and prevented…

This study tested a new drug called TAK-186 in 95 adults with advanced or metastatic cancers of the head and neck, lung, or colon that could not be removed by surgery. The main goal was to check for side effects and find the best dose. The study was stopped early, so results are …